In addition to its antifibrotic effects, the FG-3019 anti-CTGF antibody used here has also been shown to attenuate tumor growth, metastasis and angiogenesis in mouse models of pancreatic cancer and to attenuate the anchorage-independent growth of CTGF-overexpressing pancreatic cancer cells [44-46]. This evidence concerns the gene CCN2 and neoplasm.